Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase 1
Completed
NCT03239145
| Condition | Advanced Solid Tumor |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Dana-Farber Cancer Institute |
|---|
| Status | Completed |
|---|
| Enrollment | 62 participants |
|---|
| Interventions | Pembrolizumab, Trebananib |
|---|
| Start date | May 1, 2018 |
|---|
| Completion date | Dec 13, 2024 |
|---|
| Results posted | Mar 12, 2026 |
|---|
Summary
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: * Pembrolizumab * AMG386
Number of Participants Experienced Dose Limit Toxicities (DLT)
3 weeks · Participants
| [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | 0 Participants |
|---|
| [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | 0 Participants |
|---|
Maximum Tolerated Dose (MTD) of Trebananib
3 weeks · mg/kg
| [Dose Escalation Dose Level I and Dose Level II] Pembrolizumab + Trebananib | 30 mg/kg |
|---|
Grade 3 or Higher Toxicity Rate in Expansion Cohort
The median follow up time was 3.3 months (range: 0.6 to 25.3 months). · percentage of participants
| [Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 59.5 percentage of participants |
|---|
| Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 63.6 percentage of participants |
|---|
| Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 75.0 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.